Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas.
This paper illustrates the efficacy of DNA vaccination through electroporation in the prevention of oral transplantable carcinoma in Syrian hamsters. At 21 and 7 days before tumour challenge, 19 hamsters were vaccinated with plasmids coding for the extracellular and transmembrane domains of rat HER-2 receptor (EC-TM plasmids), whereas 19 control hamsters were injected intramuscularly with the empty plasmid. Immediately following plasmid injection, hamsters of both groups received two square-wave 25 ms, 375 V cm(-1) electric pulses via two electrodes placed on the skin of the injection area. At day 0, all hamsters were challenged in the submucosa of the right cheek pouch with HER-2-positive HCPC I cells established in vitro from an 7,12-dimethylbenz[a]anthracene-induced oral carcinoma. This challenge gave rise to HER-2-positive buccal neoplastic lesions in 14 controls (73.37%), compared with only seven (36.8%, P<0.0027) vaccinated hamsters. In addition, the vaccinated hamsters displayed both a stronger proliferative and cytotoxic response than the controls and a significant anti-HER-2 antibody response. Most of the hamsters that rejected the challenge displayed the highest antibody titres. These findings suggest that DNA vaccination may have a future in the prevention of HER-2-positive human oral cancer.
Berta
G N
GN
Department of Clinical and Biological Sciences, Ospedale San Luigi Gonzaga, University of Turin, I-10043 Orbassano, Italy. giovanni.berta@unito.it
Mognetti
B
B
Spadaro
M
M
Trione
E
E
Amici
A
A
Forni
G
G
Di Carlo
F
F
Cavallo
F
F
D000818:Animals; D000917:Antibody Formation; D019496:Cancer Vaccines / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000517:prevention & control; D049109:Cell Proliferation; D006224:Cricetinae; D018274:Electroporation; D008297:Male; D008647:Mesocricetus; D009062:Mouth Neoplasms / Q000276:immunology* / Q000517:prevention & control; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D014183:Transplantation, Heterologous; D019444:Vaccines, DNA / Q000276:immunology*
D019496:Cancer Vaccines; D018719:Erb-b2 Receptor Tyrosine Kinases; D019444:Vaccines, DNA